<DOC>
	<DOCNO>NCT01554813</DOCNO>
	<brief_summary>The clinical trial conduct Jintan City Jiangsu Province , China May , 2006 . The purpose clinical trial evaluate safety immunogenicity Hualan 's Influenza Vaccine ( Split Virion ) , Inactivated ( 0.5ml ) administer age 6 month old population .</brief_summary>
	<brief_title>Clinical Trial Inactivated Influenza Vaccine ( 0.5ml Formulation )</brief_title>
	<detailed_description>The clinical trial design randomize blind . Participants include 900 person . The clinical trial two stage : first stage select 60 subject administer test vaccine preliminary safety study ; 840 subject select second stage observation safety immunogenicity test vaccine administer large population basis first stage . There 560 subject 280 subject test group control group respectively . Venous blood subject collect immunization 4 week whole immunization analysis immunogenicity . The information adverse reactions/time report SFDA every month trial status blinding . Unblinding conducted subject follow-up observation .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Inclusion criterion primary vaccination subject 3 year old subject 6 months～3 year old Healthy male female 6 month , subject ( guardian ) able understand sign inform consent Healthy person inquire illness history , physical examination clinical judgment complies vaccination product Be able comply requirement clinical trial protocol Have history influenza vaccination within past 6 month vaccination product within late 1 week ; Axillary temperature＜37.1℃ . 2 . Inclusion criterion boost vaccination subject age 6 months～3 year Have history vaccination preventive product within late 1 week ; Axillary temperature＜37.1℃ . 1 . Exclusion criterion primary vaccination subject 3 year old subject age 6 months～3 year Serious disease , : tumor , autoimmunity disease , progressive atherosclerotic disease diabetes complication , COPD need oxygen uptake treatment , acute progressive liver kidney disease , CHF , etc . Subjects allergic component test vaccine ( history vaccination allergy ) , especially allergic egg History symptom sign neurological system Known suspect ( high risk onset ) damage abnormal immunologic function need receive immunosuppressant immunopotentiator treatment ; history receive immunoglobulin blood product plasma extractive outside gastrointestinal tract within past 3 month ; HIV infection relevant diseases Haemorrhage physique extension haemorrhage time History influenza least influenza vaccination within past 6 month History receive vaccination injection immunoglobulin test drug within past 1 week History acute disease infection need antibiotic antiviral treatment whole body within past 7 day History fever within past three day ( axillary temperature≥37.1℃ ) Participating another clinical trial History allergy , eclampsia , epilepsy , encephalopathy mental disease family disease ; Thrombopenia coagulopathy may cause contraindication intramuscular injection Serious chronic disease ( Down syndrome , diabetes , sickle cell anemia neurologic disease , GBS ) Known suspect disease time , include : respiratory system disease , acute infection active stage chronic disease , HIV infection infant mother , CVD , serious hypertension , treatment tumor skin disease Any condition may affect trial assessment judgment investigator . 2 . Exclusion criterion boost vaccination subject age 6 months～3 year History receive vaccination injection immunoglobulin test drug within past 1 week History acute disease infection need antibiotic antiviral treatment whole body within past 7 day History fever within past three day ( axillary temperature≥37.1℃ ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Influenza Vaccine , Vaccination ,</keyword>
</DOC>